Antibody response and avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children
- PMID: 21837801
- DOI: 10.1002/jmv.22134
Antibody response and avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children
Abstract
Respiratory syncytial virus (RSV) is a major cause of acute respiratory disease in infants and young children. Considering that several aspects of the humoral immune response to RSV infection remain unclear, this study aimed to investigate the occurrence, levels, and avidity of total IgG, IgG1, and IgG3 antibodies against RSV in serum samples from children ≤5 years old. In addition, a possible association between antibody avidity and severity of illness was examined. The occurrence and levels of RSV-specific IgG depended on age, with infants <3 months old displaying high levels of antibodies, which were probably acquired from the mother. Children ≥24 months old also showed frequent occurrence and high levels of IgG, which was produced actively during infection. In addition, the avidity assay showed that the avidity of RSV-specific total IgG and IgG1 was lower in infants <3 months old who had acute respiratory disease than in age-matched controls. The avidity of RSV-specific IgG detected in children ≥24 months old with lower respiratory infection was lower than that in children with upper respiratory infection. These results indicate that the presence of high avidity RSV-specific IgG antibodies may lead to better protection against RSV infection in children <3 months old, who may have a lower probability of developing disease of increased severity. In addition, children ≥24 months old with RSV-specific IgG antibodies of low avidity tended to develop more severe RSV illness. These findings may be helpful in establishing vaccination schedules when a vaccine becomes available.
Copyright © 2011 Wiley-Liss, Inc.
Similar articles
-
Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique.J Med Virol. 2002 Aug;67(4):616-23. doi: 10.1002/jmv.10148. J Med Virol. 2002. PMID: 12116014
-
Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls.Pediatrics. 1995 Apr;95(4):500-5. Pediatrics. 1995. PMID: 7700748
-
[Detection of respiratory syncytial virus in children with respiratory tract infections by nucleic acid amplification fluorogenic quantitative assay].Zhongguo Dang Dai Er Ke Za Zhi. 2009 Oct;11(10):825-8. Zhongguo Dang Dai Er Ke Za Zhi. 2009. PMID: 19849942 Chinese.
-
Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.Adv Ther. 2011 Feb;28(2):110-25. doi: 10.1007/s12325-010-0101-y. Epub 2011 Feb 4. Adv Ther. 2011. PMID: 21318605 Review.
-
Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?Curr Opin Infect Dis. 2015 Jun;28(3):221-4. doi: 10.1097/QCO.0000000000000161. Curr Opin Infect Dis. 2015. PMID: 25918956 Review.
Cited by
-
Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf.Sci Rep. 2018 Feb 14;8(1):3021. doi: 10.1038/s41598-018-21292-2. Sci Rep. 2018. PMID: 29445124 Free PMC article.
-
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.EBioMedicine. 2017 Feb;16:124-135. doi: 10.1016/j.ebiom.2017.01.014. Epub 2017 Jan 16. EBioMedicine. 2017. PMID: 28111238 Free PMC article.
-
Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.J Infect Dis. 2017 Dec 12;216(11):1398-1406. doi: 10.1093/infdis/jix489. J Infect Dis. 2017. PMID: 29029312 Free PMC article.
-
A Prospective Study of Immune Response After COVID-19 or Vaccination and Correlation Between Avidity Index and Neutralizing Capacity.Adv Virol. 2025 Jun 16;2025:2265813. doi: 10.1155/av/2265813. eCollection 2025. Adv Virol. 2025. PMID: 40551849 Free PMC article.
-
Utility of the Neonatal Calf Model for Testing Vaccines and Intervention Strategies for Use against Human RSV Infection.Vaccines (Basel). 2019 Jan 8;7(1):7. doi: 10.3390/vaccines7010007. Vaccines (Basel). 2019. PMID: 30626099 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical